Roche has received the EU CE mark for its Port Delivery Platform containing Susvimo, now known as Contivue in the EU. This platform, along with Susvimo, is under review by the EMA for treating neovascular age-related macular degeneration (nAMD). Contivue with Susvimo offers continuous delivery of ranibizumab directly to the eye, aiming to maintain vision with as few as two treatments per year. Seven-year data from the LADDER study show sustained visual outcomes and stable retinal anatomy with this treatment. Patients treated with Contivue with Susvimo achieved and maintained vision comparable to monthly injections in the Archway study. The technology utilizes a refillable eye implant surgically inserted in an outpatient procedure. Contivue with Susvimo is already approved in the US for nAMD, diabetic macular edema (DME), and diabetic retinopathy (DR). Roche is also developing other molecules for potential use with this port delivery platform. nAMD is a leading cause of vision loss in individuals over 60. Roche is committed to advancing ophthalmology with innovative therapies.